iRhythm’s Wearable Monitor Found Heart Arrhythmias. It Didn’t Stop Strokes.
The Zio found AFib in 5% of those who wore it, compared with 3.3% in the group that didn’t get the heart monitor. Most of ...
GlobalData on MSN2mon
iRhythm’s Zio ECG monitoring system secures Japanese regulatory approval
The Japanese Pharmaceutical and Medical Device Agency (PMDA) has approved iRhythm Technologies’ Zio ECG monitoring system, an ...
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) ...
Investing24d
FDA clears iRhythm's updated Zio AT cardiac device
The company also entered into an exclusive licensing agreement with BioIntelliSense, Inc., enhancing its ambulatory cardiac monitoring offerings. iRhythm's Zio ECG monitoring system received ...
Yahoo Finance24d
iRhythm secures 510(k) clearance for Zio device updates after FDA warning
The Zio AT device is designed to capture and send data on both symptomatic and asymptomatic heart events, continuously recording ECG for long-term monitoring. It is cleared for patients aged 18 ...
Yahoo Finance25d
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
which is used for the provision of our mobile cardiac telemetry (MCT) services. The Zio AT system consists of: the Zio AT patch, an ECG monitor that continuously records ECG data for up to 14 days ...
Morningstar25d
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
The Zio AT device is intended to capture and transmit symptomatic and asymptomatic cardiac events and record continuous electrocardiogram (ECG) data for long-term monitoring. It is indicated for ...